In this Hybrid Master's Degree you will find the latest advances in Radiation Oncology and learn how to integrate them efficiently in your professional medical praxis” 

Innovations in cancer research are constantly occurring due to the high incidence of tumors in the global population. Therefore, every year, science provides new therapeutic solutions of great value. One of the fields that has experienced the greatest growth so far has been Radiation Oncology, where new equipment of varying complexity has appeared, facilitating procedures such as intraoperative radiotherapy, systemic radiotherapy or brachytherapy models. Keeping up-to-date on all these advances has become a priority for specialists. However, there are not many educational programs on the market that cover the latest trends in this professional area.  

For this reason, TECH has designed this Hybrid Master's Degree where theoretical specifications and practical management of the most powerful techniques and tools of Radiation Oncology are combined, like no other program. In its design, the program consists of two distinct stages. The first one dedicates 1,500 hours to the conceptual approach of these latest developments, from a 100% online learning platform, where there is a proliferation of interactive resources and audiovisual materials to accompany the study process. Its very complete syllabus has been designed by top experts, who will offer a personalized guide to the physician for its complete mastery.  

Also, in a second phase, the specialist will be able to develop a clinical practice in a prestigious health institution of the highest level in terms of applications of Radiation Oncology. From this center, and under the supervision of leading experts, the graduate will manipulate advanced technologies for the benefit of the therapeutic care of real patients. The on-site internship, which lasts 3 weeks, will expand their skills on everything they have assimilated in the first stage of their learning process. Therefore, they will acquire a preparation of excellence and will be at the forefront of this field of health.  

You will master, through this Hybrid Master's Degree, the criteria to be taken into account to indicate the modality of neoadjuvant or concomitant radiotherapy, according to the condition of each patient”

This Hybrid Master's Degree in Radiation Oncology contains the most complete and up-to-date program on the market. Its most outstanding features are:

• More than 100 clinical cases presented by professionals in Radiation Oncology 
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice 
• Comprehensive systematized action plans for the main pathologies in the Radiation Oncology unit 
• Presentation of practical workshops on diagnostic and therapeutic techniques for oncology patients 
• An algorithm-based interactive learning system for decision-making in the clinical situations presented throughout the course
• Practical clinical guides on approaching different pathologies 
• All this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments 
• Content that is accessible from any fixed or portable device with an Internet connection 
• Furthermore, you will be able to carry out a clinical internship in one of the best hospitals

You will have, thanks to TECH, 3 weeks of internship in one of the best clinical centers, which will be a complete immersion in the latest developments in Radiation Oncology” 

This Hybrid Master's Degree program, which has a professionalizing nature and a hybrid learning modality, is aimed at updating professionals in Radiation Oncology who require a high level of qualification. The contents are based on the latest scientific evidence, and oriented in a educational way to integrate theoretical knowledge in the medical practice, to facilitate the updating of knowledge and allow decision-making in patient management. 

Thanks to the multimedia content, developed with the latest educational technology, will allow the medical professional a situated and contextual learning, i.e., a simulated environment that will provide immersive learning programmed to train in real situations. This program is designed around Problem-Based Learning, whereby the professional must try to solve the different professional practice situations that arise throughout the program. For this purpose, students will be assisted by an innovative interactive video system created by renowned and experienced experts. 

With this innovative Hybrid Master's Degree, you will have access to multiple theoretical contents, up-to-date according to international trends"

This immersive, comprehensive and intensive program brings together the most up-to-date trends in Radiation Oncology so that you can become a specialist with a broad professional spectrum"

The syllabus of this Hybrid Master's Degree consists of several academic modules where the physician will find a broad overview of the basics of radiotherapy treatment and radiobiology. In addition, they will examine the most modern techniques that best suit specific conditions such as gynecological, urological, thoracic and central nervous system tumors, among others. In addition, the academic plan devotes special attention to the approach to pain in cancer patients and the nutritional care that these patients require. In order to master all these aspects, TECH will provide the specialist with a 100% online and interactive learning platform of the highest level.  

The theoretical materials of this program are supported by multimedia resources, such as videos and infographics, of great didactic value for your learning” 

Module 1. Principles of Radiotherapy:  Radiobiology

1.1. Biological Effects of Ionizing Radiations 

1.1.1. DNA Damage 
1.1.2. Non-clonal Effects 

1.2. Dose Fractionation 

1.2.1. Linear-Quadratic Model 
1.2.2. Time Factor in Radiotherapy 
1.2.3. Altered Subdivisions 

1.3. Oxygen Effect and Tumor Hypoxia 
1.4. Radiobiology of Brachytherapy 
1.5. Effects of Irradiation on Healthy Tissues 
1.6. Combination of Irradiation with Drugs 
1.7. Predictive Assays of Response to Radiotherapy 
1.8. Radiobiology of Re-Irradiation 
1.9. Effects of Irradiation on the Embryo and Fetus 
1.10. Radiation-Induced Carcinogenesis 

Module 2. Update on Radiotherapy for Central Nervous System Tumors (Adults) 

2.1. Low-Grade Gliomas 
2.2. High-Grade Gliomas 
2.3. Benign Brain Tumors 

2.3.1. Meningiomas 
2.3.2. Vestibular Schwannoma 
2.3.3. Neurinoma 

2.4. Pituitary Tumors 

2.4.1. Non-Functioning Adenomas 
2.4.2. Prolactinoma 
2.4.3. GH-Producing Adenoma 
2.4.4. Cushing's Disease 
2.4.5. TSH Secreting Adenomas, GnRH-Secreting Adenomas. 
2.4.6. Pituitary Carcinomas 

2.5. Spinal Cord Tumors 

2.5.1. Astrocytoma 
2.5.2. Ependymoma 
2.5.3. Meningioma 
2.5.4. Chordoma 
2.5.5. Chondrosarcoma 
2.5.6. Miscellaneous Spinal Tumors 
2.5.7. Spinal Cord Compression 
2.5.8. Medulloblastoma 
2.5.9. Craneofaringioma  

2.6. Orbital, Ocular and Optic Nerve Tumors  

2.6.1. Rhabdomyosarcoma 
2.6.2. Pineal Gland Tumors 
2.6.3. Orbital Lymphoma 
2.6.4. Ocular Melanoma 
2.6.5. Ocular Metastases 
2.6.6. Optic Nerve Glioma 
2.6.7. Optic Nerve Meningioma 

2.7. Primary cerebral Lymphoma 
2.8. Cerebral Metastases 
2.9. Arteriovenous Malformations 

Module 3. Update on Radiotherapy for ENT Tumors

3.1. Oral Cavity 

3.1.1. Lip 
3.1.2. Tongue 
3.1.3. Floor of Mouth 
3.1.4. Gum 
3.1.5. Hard Palate 
3.1.6. Retromolar Trigone 
3.1.7. Jugal Mucosa 

3.2. Oropharynx 

3.2.1. Soft Palate 
3.2.2. Tonsils 
3.2.3. Oropharyngeal Wall 
3.2.4. Base of the Tongue 

3.3. Nasopharynx 
3.4. Larynx and Hypopharynx 

3.4.1. Larynx

3.4.1.1. Glottis 
3.4.1.2. Supraglottis 
3.4.1.3. Subglottis 

3.4.2. Hypopharynx 

3.4.2.1. Pyriform Sinus 
3.4.2.2. Hypopharyngeal Wall 
3.4.2.3. Postcricoid Tumors 

3.4.3. Epidermoid Carcinoma Variants 

3.4.3.1. Verrucous Carcinoma 
3.4.3.2. Sarcomatoid Carcinoma 
3.4.3.3. Neuroendocrine Carcinoma 

3.5. Nasal and Paranasal Sinuses 

3.5.1. Nasal Vestibule 
3.5.2. Nasal Cavity and Ethmoid Sinus 
3.5.3. Maxillary Sinus 

3.6. Salivary Glands 
3.7. Thyroid 

3.7.1. Papillary Carcinoma 
3.7.2. Follicular Carcinoma 
3.7.3. Spinal Cord Carcinoma 
3.7.4. Anaplastic Carcinoma 
3.7.5. Primary Thyroid Lymphoma 

3.8. Cervical Lymph Node Metastases of Unknown Origin

Module 4. Update on Radiotherapy for Thoracic Tumors (Pulmonary, Pleural, Cardiac) 

4.1. Non-Small Cell Lung Cancer 

4.1.1. General Information on Non-Small Cell Lung Cancer 
4.1.2. Early Stage Radiotherapy Treatment 
4.1.3. Radical Radiotherapeutic Treatment in Locally Advanced Stages 
4.1.4. Postoperative Radiotherapy Treatment 
4.1.5. Palliative Radiotherapy Treatment 

4.2. Small Cell Lung Cancer 

4.2.1. General Information on Small-Cell Lung Cancer 
4.2.2. Thoraxic Radiotherapy Treatment in Limited-Disease 
4.2.3. Radiotherapeutic Treatment in Extended-Disease 
4.2.4. Prophylactic Cranial Irradiation 
4.2.5. Palliative Radiotherapy Treatment 

4.3. Uncommon Thoracic Tumors 

4.3.1. Thymic Tumors 

4.3.1.1. General Information on Thymic Tumors 
4.3.1.2. Radiotherapeutic Treatment of Thymic Carcinoma 
4.3.1.3. Radiotherapeutic Treatment of Thymomas 

4.3.2. Carcinoid Lung Tumors 

4.3.2.1. General Information on Carcinoid Lung Tumors 
4.3.2.2. Radiotherapeutic Treatment of Carcinoid Lung Tumors 

4.3.3. Mesothelioma 

4.3.3.1. General Information on Mesotheliomas 
4.3.3.2. Radiotherapy Treatment of Mesotheliomas (Adjuvant, Radical, Palliative) 

4.4. Primary Cardiac Tumors 

4.4.1. General Information on Cardiac Tumors 
4.4.2. Radiotherapeutic Treatment of Cardiac Tumors 

4.5. Pulmonary Metastases 

4.5.1. General Information on Pulmonary Metastases 
4.5.2. Definition of Oligometastatic Lung Status 
4.5.3. Radiotherapeutic Treatment in Pulmonary Oligometastases 

Module 5. Update on Radiotherapy for Breast Tumors 

5.1. Introduction Infiltrating Breast Cancer 

5.1.1. Etiology 
5.1.2. Epidemiology 
5.1.3. Advantages of Screening: Overdiagnosis and Cost Overruns 
5.1.4. Clinical and Pathological Staging 
5.1.5. Radiological Diagnosis 
5.1.6. Histological Diagnosis: Molecular Subtypes 
5.1.7. Prognosis 

5.2. General Information on Radiotherapeutic Treatment of Breast Cancer 

5.2.1. Simulation Process: Positioning and Immobilization Systems 
5.2.2. Image Acquisition and Volume Delimitation 
5.2.3. Techniques: 3D-CRT, Evidence of IMRT/VMAT Use in Breast Cancer 
5.2.4. Dosage, Fractionation and Constraints 
5.2.5. Breath Hold 
5.2.6. Image-Guided Radiation Therapy (IGRT) 
5.2.7. Radiotherapy in the Presence of Cardiac Devices 

5.3. Indications for Radiotherapy on the Breast After Conservative Treatment in Infiltrating Breast Cancer 

5.3.1. Exclusive Preoperative Radiotherapy 
5.3.2. Adjuvant Radiotherapy After Conservative Surgery and/or Primary Systemic Therapy 
5.3.3. Evidence in Subdivisions 
5.3.4. Better Conservative Treatment than Mastectomy? 
5.3.5. Radiotherapy according to Molecular Subtype? 

5.4. Indications for Radiotherapy after Mastectomy in Infiltrating Breast Cancer 

5.4.1. Radiotherapy Post Mastectomy According to Type of Surgery 
5.4.2. Radiotherapy Post Mastectomy in N0 Cancer Radiotherapy according to Molecular Subtype? 
5.4.3. Radiotherapy Post Mastectomy in Complete Response After Primary Systemic Treatment 
5.4.4. Rib Wall Hypofractionation 
5.4.5. Inflammatory Carcinoma 

5.5. Radiotherapy and Postmastectomy Breast Reconstruction 

5.5.1. Types of Surgery (Radical Mastectomy, Skin Sparing, CAP Preservation, etc) 
5.5.2. Types of Reconstruction and Advantages/Disadvantages of RT Before or After RT 
5.5.3. Hypofractionation in Reconstructed Patient 

5.6. Management of the Axilla for the Radiation Oncologist Radiotherapy Indication in Chains 

5.6.1. Nodal Staging in Diagnosis and Sentinel Node Detection Methods 
5.6.2. RT After Lymphadenectomy and After Positive Sentinel Gland at the Time of Surgery 
5.6.3. RT After Sentinel Node Before/After Primary Systemic Therapy 
5.6.4. Hypofractionation in Chains 
5.6.5. Risk of Plexopathy 

5.7. Boost: Indications and Radiotherapy Techniques 

5.7.1. Justification for the Implementation of the Boost 
5.7.2. Indications After Conservative Surgery, Oncoplastic Surgery and Mastectomy 
5.7.3. External Radiotherapy Techniques Simultaneous Integrated Boost (SIB) 
5.7.4. Brachytherapy 
5.7.5. Intraoperative Radiotherapy (IORT) 

5.8. Partial Breast Irradiation: Indications and Radiotherapy Techniques 

5.8.1. Justification for Performing Magnetic Particle Imaging (MPI) 
5.8.2. Preoperative Radiotherapy 
5.8.3. External Radiotherapy RTC3D. Intensity-Modulated Radiation Therapy (IMRT) SBRT 
5.8.4. Brachytherapy 
5.8.5. Intraoperative Radiotherapy (IORT) 

5.9. Radiotherapy in Non-Invasive Carcinoma 

5.9.1. Introduction 

5.9.1.1. Etiology 
5.9.1.2. Epidemiology 
5.9.1.3. Advantages of Screening 

5.9.2. Indications After Conservative Surgery and Evidence After Mastectomy 
5.9.3. Genetic platform in Ductal Carcinoma In Situ (DCIS) 

5.10. Radiotherapy and Systemic Treatment 

5.10.1. Concomitant Radiotherapy/Chemotherapy 

5.10.1.1. Neoadjuvant. 
5.10.1.2. Inoperable 
5.10.1.3. Adjuvant 

5.10.2. Sequence with Systemic Treatment. Is it Possible to Administer Radiotherapy Prior to Chemotherapy After Surgery? 
5.10.3. Radiotherapy and Hormonal Therapy (Tamoxifen, Aromatase Inhibitors): Evidence for their Sequential Administration: Is Concomitance Better? 
5.10.4. Chemotherapy Followed by Radiotherapy Without Surgery? 
5.10.5. Association Radiotherapy and Anti-Her2 Teatment (Trastuzumab and Pertuzumab) 
5.10.6. Possible Toxicities of the Association 

5.11. Evaluation of the Response Follow up.  Treatment of Locoregional Recurrences: Re-Irradiation 
5.12. Locoregional Radiotherapy in Metastatic Breast Cancer Treatment of Oligometastases. Stereotactic Body Radiotherapy (SBRT).  Radiotherapy and Immunotherapy 
5.13. Male Breast Cancer and Other Breast Tumors: Paget's Disease; Phyllodes; Primary Lymphoma 

Module 6. Update on Radiotherapy for Digestive Tumors 

6.1. Esophageal Tumors 

6.1.1. General Information on Esophageal Tumors 
6.1.2. Radical Treatment of Cervical Esophageal Cancer 
6.1.3. Radical Treatment of Thoracic Esophageal Cancer 
6.1.4. Adjuvant Treatment of Thoracic Esophageal Cancer 
6.1.5. Palliative Radiotherapy Treatment 

6.2. Gastric and Gastroesophageal Junction Tumors 

6.2.1. General Information About Gastric and Gastroesophageal Junction Cancer 
6.2.2. Neoadjuvant Radiochemotherapy 
6.2.3. Adjuvant Radiochemotherapy 
6.2.4. Role of Radiotherapy in the Context of Perioperative Chemotherapy 
6.2.5. Radical Radiochemotherapy 
6.2.6. Palliative Radiotherapy Treatment 

6.3. Pancreatic Tumors 

6.3.1. Overview of Pancreatic Cancer 
6.3.2. Role of Radiotherapy in Resectable Tumors 
6.3.3. Role of Radiotherapy in Potentially Resectable Tumors (Borderline) 
6.3.4. Role of Radiation Therapy in Unresectable Tumors 
6.3.5. Role of Radiotherapy in Inoperable Tumors 
6.3.6. Palliative Radiotherapy Treatment 

6.4. Hepatobiliary Tumors 

6.4.1. General Information on Hepatobiliary Tumors 
6.4.2. Hepatocellular Carcinoma 
6.4.3. Gallbladder Cancer 
6.4.4. Cholangiocarcinoma 
6.4.5. Liver Metastases 

6.5. Colorectal Cancer 

6.5.1. General Information on Colorectal Tumors 
6.5.2. Neoadjuvant Treatment in Rectal Cancer 
6.5.3. Adjuvant Treatment in Rectal Cancer 
6.5.4. Radical Treatment in Rectal Cancer 
6.5.5. Radiotherapeutic Treatment of Recurrences Reirradiation 
6.5.6. Role of Radiation Therapy in Colon Cancer 
6.5.7. Palliative Radiotherapy Treatment 

6.6. Anal Canal and Perianal Skin Cancer 

6.6.1. Overview of Anal Canal and Perianal Skin Cancer 
6.6.2. Role of Radiotherapy in Early Tumors and Carcinoma In Situ 
6.6.3. Radical Treatment of Locally Advanced Tumors 
6.6.4. Palliative Radiotherapy Treatment 

Module 7. Update on Radiotherapy for Gynecologic Tumors

7.1. Endometrial Cancer 

7.1.1. Epidemiological Aspects 
7.1.2. Risk Factors 
7.1.3. Anatomy Recap. 
7.1.4. Histological Type 
7.1.5. Dissemination Pathways 
7.1.6. Classification 
7.1.7. Prognostic Factors 
7.1.8. Surgical Management 
7.1.9. Adjuvant Early Stage Radiotherapy Treatment 
7.1.10. Advanced Disease 
7.1.11. Local, Regional, Distant Recurrence 
7.1.12. Monitoring 

7.2. Uterine Sarcomas 

7.2.1. Epidemiological Aspects 
7.2.2. Risk Factors 
7.2.3. Anatomy Recap. 
7.2.4. Histological Type 
7.2.5. Dissemination Pathways 
7.2.6. Classification 
7.2.7. Prognostic Factors 
7.2.8. Surgical Management 
7.2.9. Adjuvant Early Stage Radiotherapy Treatment 
7.2.10. Advanced Disease 
7.2.11. Local, Regional, Distant Recurrence 
7.2.12. Monitoring 

7.3. Cervical Cancer 

7.3.1. Epidemiological Aspects 
7.3.2. Risk Factors 
7.3.3. Anatomy Recap. 
7.3.4. Histological Type 
7.3.5. Dissemination Pathways 
7.3.6. Classification 
7.3.7. Prognostic Factors 
7.3.8. Surgical Management 
7.3.9. Adjuvant Early Stage Radiotherapy Treatment 
7.3.10. Advanced Disease 
7.3.11. Local, Regional, Distant Recurrence 
7.3.12. Monitoring 

7.4. Vulvar Cancer 

7.4.1. Epidemiological Aspects 
7.4.2. Risk Factors 
7.4.3. Anatomy Recap. 
7.4.4. Histological Type 
7.4.5. Dissemination Pathways 
7.4.6. Classification 
7.4.7. Prognostic Factors 
7.4.8. Surgical Management 
7.4.9. Adjuvant Early Stage Radiotherapy Treatment 
7.4.10. Advanced Disease 
7.4.11. Local, Regional, Distant Recurrence 
7.4.12. Monitoring 

7.5. Vagina Cancer 

7.5.1. Epidemiological Aspects 
7.5.2. Risk Factors 
7.5.3. Anatomy Recap. 
7.5.4. Histological Type 
7.5.5. Dissemination Pathways 
7.5.6. Classification 
7.5.7. Prognostic Factors 
7.5.8. Surgical Management 
7.5.9. Adjuvant Early Stage Radiotherapy Treatment 
7.5.10. Advanced Disease 
7.5.11. Local, Regional, Distant Recurrence 
7.5.12. Monitoring 

7.6. Fallopian Tube and Ovarian Cancer 

7.6.1. Epidemiological Aspects 
7.6.2. Risk Factors 
7.6.3. Anatomy Recap. 
7.6.4. Histological Type 
7.6.5. Dissemination Pathways 
7.6.6. Classification 
7.6.7. Prognostic Factors 
7.6.8. Surgical Management 
7.6.9. Adjuvant Early Stage Radiotherapy Treatment 
7.6.10. Advanced Disease 
7.6.11. Local, Regional, Distant Recurrence 
7.6.12. Monitoring 

Module 8. Update on Radiotherapy for Prostate and Other Urologic Tumors

8.1. Prostate Cancer 

8.1.1. Low-Risk 
8.1.2. Intermediate Risk 

8.1.2.1. Definition of Intermediate Risk Prostate Cancer 
8.1.2.2. Subclassification of Intermediate Risk Prostate Cancer 

8.1.2.2.1. Importance of Gleason 7 

8.1.2.3. Diagnosis and Extension Study 
8.1.2.4. Treatment 

8.1.2.4.1. Active Surveillance 
8.1.2.4.2. Radical Prostatectomy 
8.1.2.4.3. Radiotherapy Techniques and Requirements 

8.1.2.4.3.1. Role of External Radiation Therapy 
8.1.2.4.3.2. The Role of Brachytherapy 
8.1.2.4.3.3. The Role of Stereotactic Body Radiotherapy SBRT 
8.1.2.4.3.4. Combined Treatments 

8.1.2.4.4. Hormone Therapy. When and How Much? 
8.1.2.4.5. The Best Option for Each Patient 

8.1.2.5. Monitoring 
8.1.2.6. Conclusions 

8.1.3. High-Risk 
8.1.4. Local and/or Distant Relapse Treatment 

8.1.4.1. Treatment of Local Relapse 

8.1.4.1.1. After Prostatectomy 
8.1.4.1.2. After Radiotherapy 

8.1.4.1.2.1. Rescue Surgery 
8.1.4.1.2.2. Rescue Cryotherapy 
8.1.4.1.2.3. Rescue Brachytherapy 
8.1.4.1.2.4. High Intensity Focused Ultrasound (HIFU) 
8.1.4.1.2.5. Intermittent Hormone Rescue 

8.1.4.2. Treatment of Distant Relapse 

8.1.4.2.1. Metastatic Patient 
8.1.4.2.2. Oligorecurrent Patient 

8.1.4.2.2.1. Hormonal Treatment 
8.1.4.2.2.2. Surgical Management 
8.1.4.2.2.3. SBRT treatment 

8.2. Preoperative and Postoperative Radiotherapy in Bladder Cancer 

8.2.1. Introduction 
8.2.2. Preoperative Radiotherapy 

8.2.2.1. Bibliographic Review 
8.2.2.2. Indications 

8.2.3. Postoperative Radiotherapy 

8.2.3.1. Bibliographic Review 
8.2.3.2. Indications 

8.2.4. Organ Conservative Treatment 

8.3. Testicular Tumors 

8.3.1. Introduction 
8.3.2. Histological Type 
8.3.3. TNM Classification and Prognostic Groups 
8.3.4. Germinal Tumors: Treatment According to Stage and Prognostic Group 

8.3.4.1. Seminoma 
8.3.4.2. Non-Seminoma 

8.3.5. Toxicity of Chemotherapy and Radiotherapy 
8.3.6. Secondary Neoplasms 
8.3.7. Non-Germ Cell Tumours 

8.4. Renal, Ureteral, and Urethral Tumors 

8.4.1. Renal Tumors 

8.4.1.1. Clinical Presentation 
8.4.1.2. Diagnosis 
8.4.1.3. Localized Disease Treatment 
8.4.1.4. Advanced Disease Treatment 

8.4.2. Urethral Tumors 

8.4.2.1. Clinical Presentation: Men vs. Women 
8.4.2.2. Diagnosis 
8.4.2.3. Treatment 

8.4.3. Ureter and Renal Pelvis Tumors 

8.4.3.1. Risk Factors 
8.4.3.2. Presentation: Primary Tumor-Metastasis 
8.4.3.3. Symptoms/Clinical 
8.4.3.4. Diagnosis 
8.4.3.5. Localized Disease Treatment 
8.4.3.6. Advanced Disease Treatment 

8.5. Penile Cancer 

8.5.1. Adjuvant Treatment 
8.5.2. Radical Treatment 

8.6. Treatment of Adrenal Metastases 

8.6.1. Introduction 
8.6.2. Surgery 
8.6.3. SBRT 

Module 9. Update on Radiotherapy for Low Incidence and Miscellaneous Tumors

9.1. Orbital and Ocular Tumors 

9.1.1. Orbital tumors 

9.1.1.1. Rhabdomyosarcoma 
9.1.1.2. Lacrimal Gland Tumors 
9.1.1.3. Orbital Metastases 
9.1.1.4. Orbital Pseudotumor 
9.1.1.5. Graves-Basedow Ophthalmopathy 

9.1.2. Tumors and Ocular Pathology 

9.1.2.1. Choroidal Melanoma 
9.1.2.2. Choroidal Metastasis 
9.1.2.3. Primary Ocular Lymphoma 
9.1.2.4. Pterigyum 
9.1.2.5. Macular Degeneration 
9.1.2.6. Choroidal Hemangioma 

9.2. Cutaneous Tumors 

9.2.1. Melanoma 
9.2.2. Non-Melanoma Skin Tumors 

9.2.2.1. Basal Cell Carcinoma 
9.2.2.2. Squamous cell carcinoma 
9.2.2.3. Merkel Cells Carcinoma 
9.2.2.4. Adnexal Carcinomas 

9.3. Soft Tissue Sarcomas and Bone Tumors 

9.3.1. Soft Tissue Sarcomas of the Extremities and Trunk 
9.3.2. Retroperitoneal and Pelvic Sarcomas 
9.3.3. Head and Neck Sarcomas 
9.3.4. Dermatofibrosarcoma Protuberans 
9.3.5. Desmoid Tumor 
9.3.6. Bone Sarcomas 

9.3.6.1. Ewing Sarcoma 
9.3.6.2. Osteosarcoma 
9.3.6.3. Chondrosarcoma 
9.3.6.4. Chordoma 

9.4. Hematological Tumors and Associated Techniques 

9.4.1. Hodgkin's Lymphomas 
9.4.2. Non-Hodgkin's Lymphomas 
9.4.3. Multiple Myeloma 
9.4.4. Plasmacytoma 
9.4.5. Mycosis Fungoides 
9.4.6. Kaposi's Sarcoma 
9.4.7. Total Body Irradiation, Total Nodal Irradiation 

9.5. Pediatric Tumors 

9.5.1. Central Nervous System Tumors 
9.5.2. Soft Tissue Sarcomas 
9.5.3. Bone Sarcomas 
9.5.4. Wilms Tumor 
9.5.5. Retinoblastoma 
9.5.6. Neuroblastoma
9.5.7. Leukemias and Lymphomas 

9.6. Benign Pathology 

9.6.1. Benign Joint and Tendon Diseases 
9.6.2. Benign Connective and Skin Diseases 

9.6.2.1. Keloids 
9.6.2.2. Plantar Fasciitis 
9.6.2.3. Gynecomastia 

9.6.3. Benign Bone Tissue Diseases 

9.6.3.1. Heterotopic Ossification 
9.6.3.2. Vertebral Hemangiomas 
9.6.3.3. Pigmented Villonodular Synovitis 
9.6.3.4. Aneurysmal Bone Cyst 

Module 10. Pain and Nutrition in Radiation Oncology

10.1. General Information on Oncologic Pain 

10.1.1. Epidemiology 
10.1.2. Prevalence 
10.1.3. Impact of Pain 
10.1.4. Multidimensional Concept of Cancer Pain 

10.2. Characterization of Pain 

10.2.1. Types of Oncologic Pain 
10.2.2. Evaluation of Oncologic Pain 
10.2.3. Prognosis of Pain 
10.2.4. Classification 
10.2.5. Diagnostic Algorithm 

10.3. General Principles of Pharmacological Treatment 
10.4. General Principles of Radiotherapy Treatment 

10.4.1. External Radiotherapy 
10.4.2. Dosages and Fractions 

10.5. Bisphosphonates 
10.6. Radiopharmaceuticals in the Management of Metastatic Bone Pain 
10.7. Pain in Long-Term Survivors 
10.8. Nutrition and Cancer 

10.8.1. Concept of Malnutrition 
10.8.2. Prevalence of Malnutrition 
10.8.3. Causes and Consequences of Malnutrition in Oncology Patients 
10.8.4. Mortality and Survival 
10.8.5. Nutritional Risk Factors in Oncology Patients 
10.8.6. Objectives of Nutritional Support 

10.9. Cachexia 
10.10. Initial Nutritional Assessment in a Radiation Oncology Service 

10.10.1. Diagnostic Algorithm 
10.10.2. Specific Treatment 
10.10.3. General Dietary Recommendations 
10.10.4. Specific Individualized Recommendations 

10.11. Nutritional Assessment During Monitoring in a Radiation Oncology Service 

The syllabus of this Hybrid Master's Degree has been designed so that you can overcome its contents in a fast and flexible way, based on the innovative learning methodology of Relearning”